Is LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 4.9% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 4.9% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 0.0% / 33% | 90.7% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 4.9% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 0.0% / 33% | 90.7% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -130.1% | |
| Return on Assets (ROA) | -68.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$3M |
| Free Cash Flow | -$3M |
| Current Ratio | 10.4 |
| Total Assets | $1M |
Price & Trading
| Last Close | $2.96 |
| 50-Day MA | $3.06 |
| 200-Day MA | $3.72 |
| Avg Volume | 66K |
| Beta | 1.0 |
|
52-Week Range
$0.64
| |
About LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), LIXTE BIOTECHNOLOGY HOLDINGS, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s debt ratio?
LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s key financial metrics?
LIXTE BIOTECHNOLOGY HOLDINGS, INC. has a market capitalization of $27M. Return on equity stands at -130.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.